Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer-Reference-Cited by-同舟云学术

Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer

Published:2023-11-28 Issue:12 Volume:2 Page:
ISSN:2766-5526
Container-title:NEJM Evidence
language:en
Short-container-title:NEJM Evidence

Author:

Freedland Stephen J.¹²,Gleave Martin³,De Giorgi Ugo⁴,Rannikko Antti⁵⁶,Pieczonka Christopher M.⁷,Tutrone Ronald F.⁸,Venugopal Balaji⁹,Woo Henry H.¹⁰¹¹,Ramirez-Backhaus Miguel¹²,Supiot Stephane¹³,Lantz Anna¹⁴,Ganguli Arijit¹⁵,Ivanova Jasmina¹⁶,Kral Pavol¹⁷,Huang Shu-Pin¹⁸,Saad Fred¹⁹,Shore Neal D.²⁰

Affiliation:

1. Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles

2. Veterans Affairs Health Care System, Durham, NC

3. The Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada

4. IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy

5. Department of Urology and Research Program in Systems Oncology, University of Helsinki, Helsinki

6. Helsinki University Hospital, Helsinki

7. U.S. Urology Partners and Associated Medical Professionals of New York, Syracuse, NY

8. Chesapeake Urology Research Associates, Towson, MD

9. Beatson West of Scotland Cancer Center, University of Glasgow, Glasgow, United Kingdom

10. SAN Prostate Center of Excellence, Sydney Adventist Hospital, Sydney

11. College of Health and Medicine, Australian National University, Canberra, ACT, Australia

12. Servicio de Urología, Fundación Instituto Valenciano de Oncología, Valencia, Spain

13. Institut de Cancérologie de l’Ouest, site Rene Gauducheau, Saint-Herblain, France

14. Karolinska Universitetssjukhuset, Solna, Sweden

15. Medical Affairs, Astellas Pharma, Northbrook, IL

16. Pfizer, New York

17. IQVIA, Bratislava, Slovakia

18. Department of Urology, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan

19. Centre Hospitalier de l’Université de Montréal, Montreal

20. Carolina Urologic Research Center/GenesisCare US, Myrtle Beach, SC

Publisher

Massachusetts Medical Society

Reference30 articles.

1. Cancer statistics, 2023

2. LONG-TERM BIOCHEMICAL DISEASE-FREE AND CANCER-SPECIFIC SURVIVAL FOLLOWING ANATOMIC RADICAL RETROPUBIC PROSTATECTOMY

3. A nomogram predicting long-term biochemical recurrence after radical prostatectomy

4. Risk of Prostate Cancer–Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy

5. Death in Patients With Recurrent Prostate Cancer After Radical Prostatectomy: Prostate-Specific Antigen Doubling Time Subgroups and Their Associated Contributions to All-Cause Mortality

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532);European Urology Oncology;2024-01

2. High-risk biochemical recurrence of locally treated prostate cancer after EMBARK. An end to decades of conventional wisdom?;Prostate Cancer and Prostatic Diseases;2023-12-08